Posted On: 08/15/2013 11:22:34 AM
Post# of 5066
There are institutions that provide flexible and very creative financing solely for life sciences and health care companies. This is an option.
The Southridge money is an option, too.
This is one of the topics I plan to explore with Dr. Koos during my visit. I haven't the faintest how much he will tel me. But, I will try to gather as much info as I can.
What I do believe you are not considering though, is that the cost of trials--especially with Orphan Drug Status--will pale compared to that of traditional trials. Further, because of the nature of the treatment and that it is a non-toxic approach, the costs associated with CT's in this case will be considerably lower than traditional trials.
The Southridge money is an option, too.
This is one of the topics I plan to explore with Dr. Koos during my visit. I haven't the faintest how much he will tel me. But, I will try to gather as much info as I can.
What I do believe you are not considering though, is that the cost of trials--especially with Orphan Drug Status--will pale compared to that of traditional trials. Further, because of the nature of the treatment and that it is a non-toxic approach, the costs associated with CT's in this case will be considerably lower than traditional trials.
(0)
(0)
